1.	Phase III Randomized Study of Paclitaxel With or Without GW572016 as First-Line Therapy in Women With Advanced or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GSK-EGF30001, NCT00075270
2.	Phase III Randomized Study of Capecitabine With Versus Without Lapatinib in Women With Refractory Locally Advanced or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GSK-EGF100151, UCLA-0403074-01, NCT00078572
3.	Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2 Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF104535, NCT00281658
4.	Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF104900, NCT00320385
5.	Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF105485, NCT00374322
6.	Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF109491, NCT00508274
7.	Phase I/II Study of Lapatinib in Patients With Recurrent Malignant Glioblastoma Multiforme Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: CAN-NCIC-IND170, NCIC-170, NCT00099060, IND170
8.	Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CRC 0503, NCT00316407
9.	GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 20 to 74 Sponsor: Pharmaceutical / Industry Protocol IDs: EGF105635, NCT00371488
10.	Phase I/II Study of Neoadjuvant Induction Chemotherapy Comprising Docetaxel, Cisplatin, and Fluorouracil Followed by Chemoradiotherapy Comprising Carboplatin and Radiation Therapy With or Without Lapatinib Ditosylate in Patients With Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: Over 18 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: EORTC-24051, EORTC-24051, EUDRACT-2006-002667-33, GSK-EORTC-24051, NCT00498953
11.	Phase II Study of GW572016 in Women With Advanced or Metastatic Breast Cancer Refractory to First-Line Trastuzumab (Herceptin) and Chemotherapy Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0208079, GSK-EGF20002, NCT00051103
12.	Phase II Study of GW572016 as Second-Line Therapy in Patients With Stage IV Colorectal Cancer Refractory to Irinotecan and Fluorouracil Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: GSK-EGF20004, UCLA-0209047
13.	Phase II Study of GW572016 in Women With Stage IIIB or IV Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: GSK-EGF20008, GSK-RM2002/00356/01, UCLA-0303056, NCT00062686
14.	Phase II Randomized Study of GW572016 as First-Line Monotherapy in Patients With Incurable Stage IIIB or Stage IV Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GSK-EGF20014, NCT00073008
15.	Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF20009, NCT00089999
16.	Phase II Study of Lapatinib in Patients With Recurrent or Persistent Endometrial Carcinoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: GOG-0229D, NCT00096447
17.	Phase II Study of Lapatinib in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Primitive Neuroectodermal Tumors, High-Grade Glioma, or Ependymoma Phase: Phase II Type: Treatment Status: Closed Age: 21 and under Sponsor: NCI Protocol IDs: PBTC-016, NCT00095940
18.	Phase II Study of Lapatinib in Patients With Hormone-Naïve Recurrent or Metastatic Hormone-Sensitive Prostate Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: PMH-PHL-030, 6706, NCI-6706, NCT00095667
19.	Phase II Study of Lapatinib in Patients With Recurrent and/or Metastatic Adenoid Cystic Carcinoma or Other Epidermal Growth Factor Receptor- and/or ERBB2-Overexpressing Malignant Tumors of the Salivary Gland Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: PMH-PHL-028, NCI-6701, 6701, NCT00095563
20.	Phase II Study of Lapatinib in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-13394, 6718, NCI-6718, NCT00098631
21.	Phase II Study of Lapatinib in Treating Brain Metastases in Patients With HER2-Positive Stage IV Breast Cancer and Brain Metastases Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: DFCI-04199, NCI-6969, 6969, NCT00098605
22.	Phase II Study of Lapatinib in Patients With Locally Advanced or Metastatic Unresectable Biliary Tract or Hepatocellular Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: CCC-PHII-53, 6674, NCI-6674, PCI-04091, NCT00101036
23.	Phase II Study of Lapatinib in Patients With Locally Advanced or Metastatic Gastric Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0413, S0413, NCT00103324
24.	Phase II Study of Lapatinib in Patients Undergoing Surgery for Recurrent Progressive Glioblastoma Multiforme or Gliosarcoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NABTC-0401, NABTC-04-01, NCI-05-C-0134, NCT00103129
25.	Phase II Study of Lapatinib in Patients With Hormone-Sensitive Recurrent Prostate Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E5803, E5803, NCT00103194